Parabilis Aims for IPO After $800M Raise to Attack 'Undruggable' Targets

Parabilis has raised $800 million and is now seeking an initial public offering, according to a report by BioPharma Dive, as the company pushes to develop medicines against targets long considered "undruggable."

The $800 million figure is the strongest signal yet of investor appetite for the company's approach. Parabilis intends to use the proceeds and a potential stock market listing to advance work on disease targets that have historically resisted conventional drug discovery, per BioPharma Dive.

The move toward an IPO comes amid a broader reopening of the biotech financing window, and Parabilis is positioning itself to capitalize on it. The company's focus on "undruggable" targets — proteins and pathways that traditional small-molecule or antibody platforms have struggled to reach — sits at the center of its pitch to public investors, BioPharma Dive reports.

For the biotechnology sector, the filing would add another sizable name to the pipeline of life-sciences listings. A successful debut would test whether public-market investors will fund the higher-risk, higher-reward biology that "undruggable" programs represent.

The next milestone to watch is the formal IPO filing, which would disclose Parabilis' financials, pipeline details and proposed valuation for the first time.